NOVACYT |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.788 EUR | -1.13% |
|
+0.13% | +10.52% |
| 05-01 | Novacyt Says UK Court Dismissed Government's Summary Judgment Application | MT |
| 05-01 | Novacyt notes court dismissal of UK DHSC summary judgment application | AN |
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors:
- development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests;
- manufacture and sale of molecular screening kits (Primerdesign): for laboratories.
Calendar
25/09/2024
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +10.52% | 59.9M | |
| -15.05% | 1.1B | |
| -22.03% | 126M | |
| +3.72% | 75.91M | |
| +5.15% | 60.02M | |
| -1.20% | 51.7M |
- Stock Market
- Equities
- ALNOV Stock
- Funds and ETFs Novacyt
